Cite

HARVARD Citation

    Persa, O. et al. (2021). Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients. Journal of immunotherapy. 44 (6), pp. 239-241. [Online]. 
  
Back to record